Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Total Debt: 2012-2024

Historic Total Debt for Ptc Therapeutics (PTCT) over the last 12 years, with Dec 2024 value amounting to $543.2 million.

  • Ptc Therapeutics' Total Debt fell 47.24% to $286.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $286.3 million, marking a year-over-year decrease of 47.24%. This contributed to the annual value of $543.2 million for FY2024, which is 13.52% up from last year.
  • According to the latest figures from FY2024, Ptc Therapeutics' Total Debt is $543.2 million, which was up 13.52% from $478.5 million recorded in FY2023.
  • In the past 5 years, Ptc Therapeutics' Total Debt ranged from a high of $643.9 million in FY2022 and a low of $330.2 million during FY2020.
  • For the 3-year period, Ptc Therapeutics' Total Debt averaged around $555.2 million, with its median value being $543.2 million (2024).
  • Per our database at Business Quant, Ptc Therapeutics' Total Debt soared by 49.24% in 2022 and then dropped by 25.68% in 2023.
  • Over the past 5 years, Ptc Therapeutics' Total Debt (Yearly) stood at $330.2 million in 2020, then skyrocketed by 30.67% to $431.4 million in 2021, then soared by 49.24% to $643.9 million in 2022, then declined by 25.68% to $478.5 million in 2023, then grew by 13.52% to $543.2 million in 2024.